Abstract:Background Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication associated with the use of antiresorptive agents, impacting patient quality of life and treatment outcomes. Predictive modeling may aid in a better understanding of MRONJ development. Purpose The study aimed to evaluate machine learning (ML)-based models for predicting MRONJ in patients receiving antiresorptive therapy.Study Design, Setting, Sample: This retrospective in silico study analyzed electronic medical records from Thammasat University Hospital, covering the period from January 2012 to December 2022. The sample included subjects receiving antiresorptive therapy, excluding those with a history of radiation therapy or metastatic jaw disease. Predictor Variables The primary predictor variable was the predicted probability of MRONJ development from the ML models. Outcome Variables The outcome variable was MRONJ status coded as present or absent based on chart review. Covariates Covariates included demographic data, MRONJ occurrence, location and staging of MRONJ, comorbidities, diseases related to antiresorptive agents, types of antiresorptive agents, therapy duration, concurrent medications, blood calcium levels, and dental factors. Analyses Model performance was assessed via accuracy, sensitivity, specificity, positive and negative predictive values, and the area under the receiver operating characteristic curve (AUROC). Additionally, univariate and multivariate Cox regression analyses were conducted to identify factors significantly associated with MRONJ development. P ≤ 0.05 was statistically significant. Results The study analyzed data from 5,305 subjects with a mean age of 75 ± 11.1 years, predominantly female. MRONJ was observed in 81 cases (1.5%), with a median time to development of 33 months (IQR = 3). Among the six models tested, the best-performing model had an accuracy of 0.95 and an AUROC of 0.89–0.90. Significant predictors identified through Cox regression included metabolic syndrome (HR = 14.064, 95% CI = 1.111–178.067, P = 0.041) and patients receiving intravenous pamidronate (HR = 5.932, 95% CI = 1.755–20.051, P = 0.004), indicating their strong association with MRONJ development. Conclusions and Relevance ML-based predictive and time-to-event models effectively predict MRONJ risk, aiding in the strategic prevention and management for patients undergoing antiresorptive therapy.

Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study

Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study

Risk Factors Influencing Medication‐Related Osteonecrosis of the Jaws (MRONJ) Following Dental Extraction Among Osteoporotic Patients in Taiwan

Medication-Related Osteonecrosis: Why the Jawbone?

Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series

Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients

Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium

Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis

Medication-related osteonecrosis of the jaw: evolving research for multimodality medical management

Risk factors for the development of medication-related osteonecrosis of the jaw and effects of tooth extraction with local infection

A retrospective study on odontogenic and non-odontogenic medication-related osteonecrosis of the jaw: Potential differences in clinical features and treatment outcomes

Three-dimensional clinical assessment for MRONJ risk in oncologic patients following tooth extractions

An institutional protocol including socket alveoplasty and primary closure following dental extractions for patients with an elevated risk of developing medication-related osteonecrosis of the jaw

Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies

A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients

A Multi-Center Observation Study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients with Osteoporosis, and Other Non-Malignant Bone Diseases, in Northwestern Italy over 16 Years

Risk Factors For Medication-Related Osteonecrosis Of The Jaw In Oncological Patients.

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases

Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy

Prediction of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients Receiving Anti-resorptive Therapy Using Machine Learning Models

Medication-Related Osteonecrosis Of The Jaw (Mronj): Successful Clinical Experiences In Treating Three Patients.